Our Research & Development Drive
Research & development has been the foundation of Boehringer Ingelheim's success and continues to be the major driver of innovative, new medicines for the treatment of diseases with an unmet therapeutic need. Furthermore, in our constant quest for pharmaceutical innovation we have successful ongoing collaborations and are actively seeking new collaborations with external partners, ranging from academic institutions to biopharmaceutical enterprises and start-up companies.
Boehringer Ingelheim's Research & Development facts:
- Our research & development comprises four major research & development sites and three support centres worldwide.
- During the past decade from 2000 to 2009, Boehringer Ingelheim conducted or sponsored 1,296 studies with 112 substances in 84 countries from all regions of the world.
- We have more than 6,900 highly qualified people working in research & development out of 41,534 Boehringer Ingelheim employees worldwide.
- Our drug discovery focuses on six major therapeutic areas: Respiratory diseases, Cardiometabolic diseases, Oncology, Neurological diseases, Immunology, Infectious diseases.
- In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro while spending more than 21% of net sales in its largest business segment Prescription Medicines on research and development.
